What is in Incruse Ellipta?
Incruse Ellipta contains umeclidinium, a long-acting muscarinic antagonist (LAMA) [1]. It is used as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) [1].
How does umeclidinium work for COPD?
Umeclidinium is a long-acting muscarinic antagonist that works by blocking the action of acetylcholine on M3 muscarinic receptors in the airway smooth muscle. This blockage leads to bronchodilation, which helps to open up the airways and improve breathing in patients with COPD [1].
When does Incruse Ellipta's patent protection end?
Information on the specific patent expiration dates for Incruse Ellipta is available through resources like DrugPatentWatch.com [2]. Patent data can indicate when generic competition might become possible.
Can generic versions of Incruse Ellipta be developed?
The development of generic versions of Incruse Ellipta would depend on patent expirations and regulatory approvals. Once patent exclusivity is lost, and if regulatory requirements are met, generic manufacturers may be able to produce and market their own versions of the drug [2].
What are the side effects of Incruse Ellipta?
Common side effects reported with Incruse Ellipta include nasopharyngitis (common cold symptoms), headache, and pain in the upper abdomen [1]. More serious side effects can occur, such as paradoxical bronchospasm, glaucoma, urinary retention, and worsening of narrow-angle glaucoma [1].
How is Incruse Ellipta administered?
Incruse Ellipta is delivered using the Ellipta inhaler. One inhalation is taken once daily [1].
What is the difference between Incruse Ellipta and other COPD inhalers?
Incruse Ellipta is a monotherapy LAMA. Other COPD inhalers may contain different classes of medications, such as long-acting beta-agonists (LABAs) or inhaled corticosteroids (ICS), or combinations of these [1]. For example, a combination inhaler might include a LABA and a LAMA. The choice of inhaler depends on the patient's specific symptoms and disease severity.
What clinical data supports Incruse Ellipta's effectiveness?
Clinical trials have demonstrated that Incruse Ellipta improves lung function, as measured by the change from baseline in pre-dose trough FEV1 (forced expiratory volume in 1 second) at 24 weeks, compared to placebo [1].
Sources
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205077s000lbl.pdf
2. https://drugpatentwatch.com/